jackie.vuistiner

Switzerland, 10 September 2025 – CUTISS, a late-stage clinical TechBio at the forefront of tissue therapeutics and regenerative medicine, has announced the closing of its Series C round for a total of CHF 56M with existing and new investors, bringing total funds raised to more than CHF 125M. The proceeds will be used to progress with the Phase 3 trial of the lead product denovoSkin™, which started earlier this year, and to prepare for its commercialization. The funds will also advance the industrialization and clinical readiness of the world’s first automated manufacturing platform for personalized tissue therapy, a key component for bringing denovoSkin™ to market at scale. Dr. Daniela Marino, CEO and co-founder of CUTISS, stated: “The successful closing and partnerships demonstrates confidence in our vision and ability to bring transformative skin therapies to patients. We’re grateful for the continued trust of existing investors and warmly welcome new investors on board, including key strategic ones.” CUTISS has also signed a collaboration agreement with its new investor Rode Kruis Ziekenhuis (RKZ), which could see the creation of CUTISS’ first international commercial production facility in the Netherlands, once denovoSkin™ is commercially approved. RKZ is a leading EU clinical trials center, participating in the Phase 2 and Phase 3 trials for denovoSkin™.   “The agreement with RKZ sets the stage for our future expansion with the potential to revolutionize the skin surgery market in Europe and globally,” continued Dr. Marino. Nadine Vieleers, CEO Rode Kruis Ziekenhuis / Burn Center Beverwijk, commented: “As a clinical institution dedicated to advancing burn care, we’re committed to support CUTISS and the development of denovoSkin™. We’re excited to continue our closer collaboration, and the agreement we’ve signed sets out our vision for bringing their revolutionary skin tissue therapy to our patients as a priority.” The Series C co-lead investors – the family office of Giammaria Giuliani, a longstanding lead investor, and a US family represented by Shiloh Advisors AG – were joined in 2025 by new investors ranging from family offices to industry players, as well as an investor collective at Swisspreneur. Silvan Krähenbühl, speaking on behalf of Swisspreneur, commented: “We’re proud that Swisspreneur participated in the latest funding round of CUTISS, a pioneering Swiss biotech company. Their mission to revolutionize skin regeneration is exactly the kind of bold innovation we love to support, and we’re excited for the next phase in the journey ahead.”  In April 2025, CUTISS announced a strategic partnership with Tecan to enable the transition of CUTISS’ automated manufacturing solution from engineering development to industrial-grade production. Monica Manotas, Tecan CEO, commented: “Our ongoing partnership with CUTISS to industrialize skin tissue therapy highlights our commitment to advancing automation in high-growth areas such as cell biology and personalized medicine. Tecan’s expertise and technologies deliver precision and reproducibility at scale, enabling customers to transform research breakthroughs into real-world solutions to improve people’s lives and health.” denovoSkin™ is human, living skin – on demand The personalized (autologous), bioengineered skin graft denovoSkin™ is designed for patients undergoing skin surgery for burns, reconstructive and plastic procedures. denovoSkin™ is bilayer, composed of both dermis and epidermis. Long-term follow-ups to date have shown that it drastically spares donor sites, matures quickly, safely restores skin function, regenerating in a near-scarless manner, and growing with the patient. As a result, it has the potential to significantly reduce healthy skin harvesting and scar care (including follow-up corrective surgeries), and improve quality of life. The Phase 3 confirmatory study in adolescent and adult severe burn patients is recruiting in Switzerland, and the European Union across 8 member states. The first data set from this trial is expected at the end of 2026. denovoSkin™ has also been accessible under named-patient basis (compassionate use). It has Orphan Drug Designation (ODD) for the treatment of burns from Swissmedic, EMA, and the FDA, which also provides fast-track regulatory pathways and extended market exclusivity. Scaling up with first-in-class automated production CUTISS is working to scale-up the production of denovoSkin™ through automation. The company has already developed a first-in-class automation platform for the scalable production of personalized tissue therapy – a patented, fully-closed, end-to-end system that enables de-centralized production, cost-effective scale-up, and high return on investment. Platform industrialization is now ongoing. VitiCell® offers personalized treatment for patients with skin pigmentation disorders CUTISS has exclusive rights to globally commercialize VitiCell®, an MDD CE-marked medical device developed by IBSA Pharma. The device enables autologous cell grafting for skin re-pigmentation, offering a personalized treatment option for patients with vitiligo. In the future, patients treated with denovoSkin™ may also benefit from this therapy. CUTISS will launch VitiCell® once the EU MDR CE marking is granted. About CUTISS Established in 2017 as a spin-off of the Tissue Biology Research Unit of the University of Zurich, CUTISS is at the forefront of tissue engineering therapy and regenerative medicine. Our lead product denovoSkin™ is a bio-engineered, personalized skin graft, that promises to transform skin surgery. Currently in Phase 3 clinical trials in Europe, denovoSkin™ has received Orphan Drug Designation from Swissmedic, the European Medicines Agency (EMA), and the US FDA for the treatment of burns. Moreover, CUTISS is pioneering the development of the world’s first automated platform for large-scale skin tissue production, advancing breakthrough programs in skin pigmentation restoration and expanding the horizons of tissue engineering. www.cutiss.com Media contacts CUTISS: CPC PR | Toomas Kull | kull@cpc-pr.com | +41 767 480 174 RKZ: Sandra de Jong | sfmdejong@rkz.nl | +31 653447246 Newsroom Press release (PDF)

Switzerland – 14 April 2025 – CUTISS, a late-stage clinical biotech at the forefront of tissue therapeutics and regenerative medicine, today announced a strategic partnership with Tecan, a global leader in the development, production, and distribution of automation solutions for the life sciences and diagnostics sector. This collaboration marks a critical step in the industrialization of CUTISS’ pioneering automation platform for the manufacturing of personalized skin tissue therapies. The partnership will enable the transition of CUTISS’ automated manufacturing solution from engineering development to industrial-grade production. It will also support CUTISS’ mission to bring its lead product denovoSkin™ – the personalized, bioengineered human skin graft – to market at scale and to expand the platform’s potential into new areas of regenerative medicine. Dr. Daniela Marino, CEO of CUTISS, said: “This collaboration reaffirms our leading role in tissue therapeutics and our commitment to take denovoSkin™ to the global market. As a late-stage clinical biotech we strongly believe that denovoSkin™ has the potential to revolutionize skin surgery globally and across numerous indications. Tecan’s expertise and global infrastructure will strengthen our industrial capabilities, enabling the rapid scale-up of our automated tissue therapy platform. We are proud to work alongside such a strong industrial leader with Swiss roots and international presence.” Dr. Achim von Leoprechting, CEO of Tecan, stated: “We are pleased to partner with CUTISS in industrializing the world’s first automated manufacturing platform for personalized skin tissue therapy, addressing unmet medical needs. This collaboration perfectly aligns with Tecan’s purpose of improving people’s lives and health by empowering customers to scale healthcare innovation globally, from life science to the clinic.” Dr. Vincent Ronfard, Chief Innovation Officer of CUTISS, added: “The CUTISS automation platform is a first-of-its-kind in personalized tissue manufacturing. Together with Tecan we are paving the future of tissue engineering automation.” denovoSkin™ in late-stage Phase 3 clinical trials As a personalized, bioengineered human skin graft, denovoSkin™ is designed for patients undergoing skin surgery for severe skin injuries (such as burns) or reconstructive procedures. It aims to replace the current standard of care, autografting, and to significantly improve patient outcomes. The Phase 3 confirmatory study in adolescent and adult severe burn patients is taking place in Switzerland and the European Union across 8 sites. denovoSkin™ is also accessible under compassionate use. It has been granted Orphan Drug Designation (ODD) for the treatment of burns from Swissmedic, EMA, and the FDA.  denovoSkin™ is unique because it is bilayer, composed of both dermis and epidermis. In clinical trials and long-term follow-ups to date, it has been shown to grow with the patient and regenerate in a scarless manner, to mature quickly, safely restore skin function, and significantly reduce the need for scar care and follow-up corrective surgeries. Beyond being life-saving and life-changing, denovoSkin™ is also cost-effective and offers attractive unit economics. Scaling up with first-in-class automated production CUTISS is working to scale-up the production of denovoSkin™ through automation. The company has already developed a first-in-class automation platform for the scalable production of personalized tissue therapy – a patented, fully-closed, end-to-end system that enables decentralized production, cost-effective scale-up, and high return on investment.  About CUTISS CUTISS (www.cutiss.com) is a late-stage clinical biotech at the forefront of tissue engineering therapy and regenerative medicine. The lead product – denovoSkin™ – is a bio-engineered, personalized human skin graft that promises to transform skin surgery with significant benefits to patients around the world. Currently in Phase III clinical trials in Europe, denovoSkin™ has received Orphan Drug Designation from Swissmedic, the European Medicines Agency (EMA), and the US FDA for the treatment of burns. CUTISS is also pioneering the development of the world’s first automated platform for large-scale skin tissue production, advancing breakthrough programs in skin pigmentation restoration and expanding the horizons of tissue engineering. To date, the project has benefited from public funding support including from Innosuisse, Switzerland’s innovation agency, and the European Union Horizon 2020. The company was established in 2017 as a spin off from the Tissue Biology Research Unit at the University of Zurich, and is headquartered in Zurich, Switzerland. About Tecan Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has 3,300 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2024, Tecan generated sales of CHF 934 million (USD 1,062 million; EUR 984 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191). Media contacts CUTISS – European and international mediaCabinet Privé de Conseils (Switzerland)Toomas Kull kull@cpc-pr.com | +41 767 480 174 Newsroom Press release (PDF)